explore -WSS

explore

author：explore 2025-09-28 16:34:51 - browse：9

insulin biosimilar — Last week, the FDA released a trio of guidelines clarifying the way they plan to evaluate devices that go through the 510(k) pathway. Jacquelyn Martin/AP

Five years after promising to fix a flawed regulatory pathway widely used by medical device manufacturers, the Food and Drug Administration has issued new guidelines to improve its so-called 510(k) program that has long been lambasted for letting risky devices fall through the cracks.

Most medical device companies do not have to test their products on people in order to secure clearance from the FDA — they simply have to show they’re “substantially equivalent” to devices already on the market, called “predicates.” This process is the 510(k) pathway, and accounts for the vast majority of new medical devices launched on the market each year. Devices cleared through this pathway include X-ray machines, muscle stimulators, and wheelchairs.

Last week, the FDA released a trio of guidelines clarifying the way it plans to evaluate devices that go through the 510(k) pathway. The agency is asking manufacturers to avoid predicate devices that were recalled due to a “design-related” issue or have “unmitigated” safety concerns. Manufacturers should submit flow charts explaining why they chose their predicate device. If they have to choose one with a recall history or safety issues, they should explain how the new device addresses those problems. The FDA may also ask the manufacturer for clinical data in this case.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Orchard's therapy for neuron disease in children wins FDA approval

entertainment

WSS

Too many hospitalized Covid

Ebola vaccine can save some who are already sick, per new study

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Artificial intelligence use in health care faces greater scrutiny in 2024

Resistance to opioid

Bernie Sanders gets little from pharma CEOs on drug prices

Wikipedia

explore

focus

Cancer drug shortages should be causing more outrage

Long Covid research funding gets a major boost from NIH

Hollywood unions extend contract negotiations for actors

Virtual Event: March of the Biosimilars

In Memoriam: Notable people who died in 2023

Artificial intelligence use in health care faces greater scrutiny in 2024

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

ACIP vaccine advisory panel sees its vacancies filled

Heart attack and stroke risk calculators need revising

Latigo launches with $135 million for Vertex

focus

Why Eli Lilly’s earnings didn’t quite live up to the hype

Intermittent fasting comes with a heart risk? Not so fast

Report cites 'urgent' need to recruit more diverse clinical trial participants

Abbott's new heart device gets FDA advisory panel nod

App could help diagnose ear infections more accurately — and at home

CVS Caremark has created a new ploy: the drug ‘rebate credit’

focus

entertainment

Wikipedia

Wikipedia